A Landmark Case: The Aftermath of Myriad Genetics
Richard M. Marsh, Executive Vice President and General Counsel for Myriad Genetics is on the panel. He started off his presentation explaining that he really wants to talk about the case and the...
View ArticleEthical Issues: Staying in the Frying Pan and out of the Fire
In the situation where there is a joint research collaboration everything is fine, people are happy and hope springs eternal right up until that moment when everything falls apart. Then you have issues...
View ArticleHouse Patent Reform Bill is in Need of Reform, BIO to Oppose
BIO has consistently praised House Judiciary Committee Chairman Lamar Smith (R-TX) for his introduction of a comprehensive patent reform bill similar to the bill adopted by the U.S. Senate earlier this...
View ArticleIndustry Urges Congress to Continue Renewable Fuel Standard
While many people believe that alternative energy is at least several decades away, what is clear is that if we do not set out about making that future a reality it will never been the future we...
View ArticleInsiders React to Supreme Court Prometheus Decision
Just over three weeks ago the United States Supreme Court issued a decision in Mayo Collaborative Services v. Prometheus Laboratories, which sent much of the patent world into a whirlwind. In that...
View ArticleBIO Lauds Senate Passage of User Fee Package
The inclusion of an enhanced Accelerated Approval pathway, crafted by Senator Kay Hagan (D-NC), will help expedite the development of modern, targeted, and personalized therapies for patients suffering...
View ArticleUniversity Licensing and Biotech IPRs Good for the Economy
Earlier in the week BIO also unveiled another report it commissioned and which was authored by Lori Pressman, David Roessner, Jennifer Bond, Sumiye Okubo, and Mark Planting. This report, titled Taking...
View ArticleBIO Hails House Passage of FDA Safety and Innovation Act
It will enhance the development and review of innovative new therapies through increased transparency and scientific dialogue, advancements in regulatory science and strengthened post-market review. It...
View ArticleThe U.S. Government’s Position in ACLU v. Myriad Genetics: Observations on a...
So maybe the Federal Circuit won’t find “preemption” to be useful in deciding this appeal; we’ll know soon enough. I, for one, can’t make sense of the DOJ’s fixation on “tying up.” In Flook, the...
View ArticleInnovator Concerns Grow over Innovation Act
Calling the Innovation Act fast-tracked doesn't do justice to what is really happening. The Innovation Act was only officially introduced on October 23, 2013, and the Committee has not heard from any...
View ArticleIn Defense of Patents and Licensing: Why the Newest Attack is Bogus
Fortunately, a new study showing that academic patent licensing contributed more than $1 trillion to the U.S. economy over eighteen years blows the stuffing right out of that straw man. We can only...
View ArticleMixed Reviews for the PATENT Act in the Senate
Microsoft applauded the introduction of the PATENT Act. Universities seem to be on the fence, recognizing that the Senate alternative is an improvement, but likely to support amendments. The Innovation...
View ArticleBIO, PhRMA lobby for IPR fix to insulate their patents from challenge
Greenwood and Castellani will have two major problems as they seek relief. First, the IPR provisions do not include a standing requirement, which means that anyone can bring an IPR for any reason. The...
View ArticleWill More Regulation Create Cheaper Drugs?
The idea of reducing drug prices through more government control is always simmering on the backburner and doesn’t require much to bring it to a full boil. Two recent actions turned up the heat to full...
View ArticleJim Greenwood to Chair BIO Ventures for Global Health Board of Directors
BIO Ventures for Global Health (BVGH) announced that Jim Greenwood, President and CEO of the Biotechnology Innovation Organization (BIO) has been elected as the new BVGH Board Chair for a term of three...
View ArticleIP Protection Critical for BioPharma Given Number, Cost and Complexity of...
Biopharmaceutical innovation is difficult, expensive, time-consuming, and risky. More so now than ever. A 2014 study by Tufts University’s Center for the Study of Drug Development calculated that a...
View ArticleAcademic Patent Licensing Helps Drive the U.S. Economy
What's even more impressive is the impacts on gross industry output and GDP are up 14% while the number of U.S. jobs supported rose 12% since the previous report issued two years ago. That's...
View ArticleThink Twice Before Pulling the Plug on Tech Transfer
Most assaults on public/private sector R&D partnerships are launched by those who believe patents are inherently bad and that through some undefined magic publicly funded inventions will be...
View ArticleSt. Regis Mohawks, BIO send letters to Senate Judiciary slamming the unfair...
On Thursday, October 12th, a pair of letters addressed to the bipartisan leadership of the Senate Judiciary Committee were delivered in an attempt to inform Senators on that committee of various issues...
View ArticleAnalyzing Amicus Briefs Filed in Support of Granting Cert. in Helsinn
On June 25th, the the U.S. Supreme Court agreed to hear Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc., on appeal from the Federal Circuit. The case will ask the Supreme Court to decide...
View Article
